Publication | Closed Access

The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma

Tumor BiologyLymphoid NeoplasiaMedicineImmunologyPathologyRelapsed Hodgkin LymphomaAdult T-cell Leukemia-lymphomaImmunotherapyOncologyCancer ResearchBrentuximab Vedotin